Syros Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James E. Bradner
- Full Time Employees
- 68
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 35 CambridgePark Drive Cambridge MA United States of America 02140
- IPO Date
- Jun 30, 2016
- CIK
- 0001556263
- Website
- syros.com
- Similar Companies
- Business
- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company, develops gene control therapies targeting hematologic malignancies and other diseases through modulation of gene expression via its proprietary platform; its pipeline includes clinical-stage candidates such as tamibarotene, an oral selective RARα agonist for relapsed/refractory acute myeloid leukemia (AML) with RARA gene overexpression and higher-risk myelodysplastic syndrome (HR-MDS), SY-2101, a novel oral formulation of arsenic trioxide for acute promyelocytic leukemia (APL), and SY-5609, a selective CDK7 inhibitor for select solid tumors including pancreatic ductal adenocarcinoma. Founded in 2011 and headquartered in Cambridge, Massachusetts, the company previously operated collaborations including a TYK2 program with Takeda for immune-mediated diseases and advanced the SELECT-MDS-1 Phase 3 trial for tamibarotene in RARA-positive HR-MDS, reporting topline data in November 2024 that did not meet the primary endpoint of complete response. In recent developments, Syros sold tamibarotene-related clinical and non-clinical assets including safety data, manufacturing contracts, and drug product to Rege Nephro on February 26, 2025; implemented a 94% workforce reduction following trial setbacks and the termination of its Pfizer collaboration; announced voluntary delisting from Nasdaq and SEC deregistration effective around March 20, 2025 due to non-compliance with listing standards including a sub-$1 share price, low market value, and covenant breaches with lender Oxford Finance; and maintains a cash position funding operations into Q3 2025 while exploring strategic alternatives for remaining programs.
Critical Analysis: Syros Pharmaceuticals (NASDAQ:SYRS) & ADVANZ PHARMA (OTCMKTS:CXRXF)
Cyclacel Pharmaceuticals (NASDAQ:BGMS) vs. Syros Pharmaceuticals (NASDAQ:SYRS) Head to Head Analysis
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm